

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/006657 A1

(51) International Patent Classification:

A61K 38/22 (2006.01) C07C 53/10 (2006.01)
A61K 31/19 (2006.01) C07K 14/575 (2006.01)
A61P 3/00 (2006.01) C07K 14/60 (2006.01)
A61P 3/04 (2006.01)

(21) International Application Number:

PCT/CA2021/050904

(22) International Filing Date:

30 June 2021 (30.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/048,167 05 July 2020 (05.07.2020) US

(71) Applicant: **THERATECHNOLOGIES INC.** [CA/CA];
2015 rue Peel, Bureau 1100, Montréal, Québec H3A 1T8
(CA).

(72) Inventors: **MARSOLAIS, Christian**; 177 Jasper Avenue,
Mount-Royal, Québec H3P 1K1 (CA). **SHINGEL, Kir-
ill**; 7525 Pelletier Boulevard, Brossard, Québec J4W 3A9
(CA). **POTVIN, Diane**; 4278 Hampton Avenue, Montréal,
Québec H4A 2K9 (CA).

(74) Agent: **LAVERY, DE BILLY, LLP**; 1, Place Ville Marie,
Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: LOW-DOSE PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF




FIG. 1

(57) Abstract: A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is *trans*-3-hexenoyl-GHRH₍₁₋₄₄₎-NH₂ or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.23 to about 1.32 mg of a GHRH molecule such as *trans*-3-hexenoyl-GHRH₍₁₋₄₄₎-NH₂ at a concentration of about 7.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of *e.g.*, *trans*-3-hexenoyl-GHRH₍₁₋₄₄₎-NH₂ that are bioequivalent to administration of 2 mg of *trans*-3-hexenoyl-GHRH₍₁₋₄₄₎-NH₂ at a concentration of 1 mg/mL in a subject are also described.

[Continued on next page]

WO 2022/006657 A1

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*